Results 151 to 160 of about 21,018 (198)

Collagen nanobubbles as efficient carriers for targeted controlled release of ibrutinib

Sena Pişkin, Handan Sevim, Canan Armutçu, Lokman Uzun   +3 more
openalex   +2 more sources

Lights and shades of front-line treatment with covalent BTK inhibitors combined with venetoclax in patients with chronic lymphocytic leukemia. [PDF]

Oncol Rev
Visentin A, Mauro FR.
europepmc   +1 more source

Tisagenlecleucel in combination with ibrutinib in adults with relapsed and/or refractory large B-cell lymphomas. [PDF]

Blood Neoplasia
Chavez JC, Napier E, Bondanza A, Lewandowski A, Mataraza J, Quinn D, Kwon P, Locke FL, Engels B, Awasthi R, Georgala P, Leyk M, Hynds D, Moschetta M, Schuster SJ.   +14 more
europepmc   +1 more source

Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL). [PDF]

Cell Death Discov
Langpape A, Bonasera D, Stroh J, Reese M, Cartolano M, Liccardi G, von Karstedt S.   +6 more
europepmc   +1 more source

Correction: Microsecond simulations to investigate the structural mechanism of super-resistant double mutations in BTK to the covalent inhibitor ibrutinib in multiple leukemia. [PDF]

Sci Rep
Khan A, Ali SS, Zahid MA, Alshabrmi FM, Al-Zoubi RM, Shkoor M, Mohammmad A, Wei DQ, Agouni A.   +8 more
europepmc   +1 more source

Tolerability and long-term disease control by IGHV mutation status among patients with CLL on ibrutinib arm of E1912

Tait D. Shanafelt, Victoria Wang, Curtis A. Hanson, Elisabeth Paietta, Susan O’Brien, Jacqueline C. Barrientos, Diane F. Jelinek, Esteban Braggio, José F. Leis, Cong Christine Zhang, Paul M. Barr, Amanda F. Cashen, Anthony R. Mato, Avina K. Singh, Michael P. Mullane, Richard F. Little, Harry P. Erba, Richard M. Stone, Mark R. Litzow, Martin S. Tallman, Neil E. Kay   +20 more
openalex   +1 more source

Patterns of Bruton's Tyrosine Kinase Inhibitor (BTKi) Usage in B-cell Lymphomas in India: A Questionnaire-Based Study. [PDF]

Cureus
Naseem A, Pednekar A, Patil S, Barkate H.   +3 more
europepmc   +1 more source

Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? [PDF]

Eur Cardiol
Esposito R, Menna P, Salvatorelli E, Camilli M, Minotti G.   +4 more
europepmc   +1 more source

Observational retrospective study of the treatment of Waldenström's macroglobulinemia with ibrutinib in routine clinical practice in Spain. [PDF]

Ther Adv Hematol
Fernández de Larrea C, Loscertales J, Cabañas V, Freiria C, Blanchard MJ, Askari E, Lorenzo Pérez M, Abril L, López Pardo J, Pinzón S, Díaz Gálvez J, Amer N, Ramírez Páyer Á, García Sánchez R, Alcalá MM, Capote FJ, Moreno D, Bolumburu C, Rubio-Azpeitia E, García Sanz R.   +19 more
europepmc   +1 more source

Onychorrhexis and onychoschizia associated with ibrutinib therapy. [PDF]

JAAD Case Rep
Baroz AR, Buist R, Mervak JE.
europepmc   +1 more source